Warp Sciences Exits Stealth With $215M to Automate Drug Discovery

The South San Francisco CRO wants to close the loop between AI, robotics, and wet-lab chemistry — and keep it all onshore.

By The Robotics Desk

Warp Sciences emerged from stealth last week with $215 million in funding to build a U.S.-based chemistry contract research organization — one that pairs medicinal chemists with robotics and AI to make and test drug compounds faster than conventional labs can manage. [1]

The South San Francisco startup's first service targets lead optimization analog synthesis: producing molecular variations that research teams compare as they close in on a drug candidate. Experienced chemists guide experiments while the lab grows progressively more automated, with AI models trained directly on data from physical runs. [1]

The timing is deliberate. A 2024 Biotechnology Innovation Organization survey found that 74% of respondents held contracts with Chinese companies for preclinical and clinical services. The BIOSECURE Act, signed into law in December 2025, established a framework restricting federal procurement from designated biotechnology companies of concern — opening a lane for domestic CROs. [1]

Warp holds no proprietary drug pipeline. [1] DJ Patil, a founding executive at Devoted Health and the first U.S. chief data scientist for the White House, put it plainly: "We're not developing drugs of our own. We're building the infrastructure for the people who do." [1]

What Warp is selling, ultimately, is time — the kind that only comes when physical experimentation stops waiting on scheduling queues and starts feeding directly into machine learning that sharpens the next hypothesis.

Lightspeed led the round, with participation from Mayfield, IVP, Lux, and Menlo Ventures, among others. [1]